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INTRODUCTION 
 
Sleep is defined as a periodic reversible physiological state of 
loss of consciousness from which a person can be aroused by adequate 
sensory stimuli and it is necessary for the recoupment and well being 
of the individual. We spend around 8 hours per day for sleep which 
means 56 hours per week, 224 hours per month and 2688 hours per 
year (ie) almost nearly 1/3 of our lives we spent for sleep. Sleep helps 
in energy conservation, physical restoration, memory reinforcement 
and consolidation, thermoregulation, preserving synaptic efficiency 
and brain plasticity, immune function, brain growth and development.2 
SLEEP DISORDERS 
The International Classification of Sleep Disorders (ICSD-2, 
2005) includes over 80 sleep disorders which can be divided into eight 
broad categories1. They are i) Insomnia ii) Sleep related breathing 
disorders  iii) hypersomnia of central origin  iv) circadian rhythm 
sleep disorders v) parasomnia  vi) sleep related movement disorders  
vii) isolated symptoms, apparently normal variants, viii) other sleep 
disorders (physiological /environmental sleep disorders).  Sleep 
related disorders affect the mood, behavior, work and quality of life 
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contributing to morbidity and mortality of the pre-existing medical 
illness.  Their recognition and treatment can help in improving the 
functional ability of the individual.  Sleep abnormalities in movement 
disorders especially parkinsonism is associated with decreased slow 
wave sleep and REM sleep, decreased total sleep time and sleep 
efficiency, prolonged sleep latency were intensively studied world 
over. 
SLEEP AND POLYSOMNOGRAPHY 
The invention of the EEG in 1929 and studies to understand 
consciousness, sleep, wakefulness in the era of 1930’s and 1940’s and 
the discovery of REM sleep in 1953 by Aserensky et al ushered in the 
golden age of sleep medicine. The objective documentation of the 
sleep and its related events is done using polysomnography (PSG).  
Based on physiologic criteria sleep is divided into two independent 
categories; Non rapid eye movement (NREM) and rapid eye 
movement (REM) sleep. 
EVALUATION OF SLEEP DISORDERS 
Approach to a patient with a sleep complaint includes, a 
detailed history of sleep, psychiatric, neurologic, medical, drug, family 
history and a standard sleep questionnaire along with 
polysomnography.  The Epworth sleepiness scale is used to measure 
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daytime sleepiness.  Various sleep questionnaires were used to assess 
the sleep disturbance. The nocturnal sleep disturbance and the daytime 
sleepiness were objectively measured by polysomnography and 
multiple sleep latency test (MSLT) respectively. 
PARKINSON’S DISEASE 
Parkinson’s disease (PD) is a progressive neurodegenerative 
disorder associated with a loss of dopaminergic nigrostriatal neurons.  
It is named after James Parkinson, the English physician who in an 
“Essay on the Shaking Palsy” in 1817 described Parkinson’s disease 
as “involuntary tremulous motion, with lessened muscular power, in 
parts not in action and even when supported, with a propensity to bend 
the trunk forward, and to pass from a walking to a running pace, the 
sense and intellect being uninjured.”  Sleep disorders have been 
mentioned since the first description of the extra-pyramidal diseases in 
James Parkinson’s Essay on the Shaking Palsy, but only recently they 
have become the subject of attention, thanks to new acquisitions in 
clinical knowledge and polysomnography technology. 
SLEEP DISTURBANCES IN PD 
Nocturnal Sleep disturbance are common in PD but it is a 
complex issue having multiple causes.  Insomnia, hypersomnia, and 
parasomnia are seen in PD.  Nighttime awakenings and inability to fall 
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back to sleep are predominant complaints.  Sleep latency is not a 
problem.  Early insomnia may be due to medications (the alerting 
effect of levodopa) and late insomnia may be contributed by 
depressive symptoms.  Hypersomnia in the form of excessive day time 
sleepiness occurs in PD.  Community based prevalence of daytime 
somnolence was found in 15% of PD patients.   
The most common parasomnia seen in PD was REM sleep 
behaviour disorder (RBD).  RBD can precede the onset of PD by a 
mean of 3.7 years. (Iranzo et al, 2006)3.  Night time sleep disturbances 
tends to be mild in early PD and the subjective sleep quality may not 
differ from age matched controls4.With advancing disease the sleep 
disturbances are more prevalent.  Even in early PD, the PSG may 
show increased muscle tone, abnormal movements during sleep like 
increased blinking, blepharospasm, tremor, periodic limb movements 
during sleep, rapid eye movement sleep behaviour disorder and 
respiratory abnormalities. 
The non-motor symptoms of PD have recently become the 
focus of attention.  In the following section the relevant studies in the 
field on non-motor symptoms of PD are discussed with particular 
emphasis on the sleep and its related complications in PD. 
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AIMS & OBJECTIVES 
 
1) To evaluate the frequency and the nature of the sleep 
abnormalities in Idiopathic parkinson’s disease. 
 
2) To analyse the sleep architecture in Parkinson’s disease using 
polysomnography and to correlate the results with the disease 
parameters. 
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REVIEW OF LITERATURE 
 
Parkinson’s disease (PD) is a progressive neuro degenerative 
disease characterised by asymmetrical motor manifestations. Although 
PD was considered primarily a motor disorder, recently the non-motor 
features like sleep disturbances, cognitive,autonomic disturbances 
have been recognized as important components of the disease causing 
significant disability.  
Clinical Features of Parkinson’s disease  
Parkinson’s disease (PD) is an age related disease which begins 
between 50 and 70 years of age, with increase in prevalence after sixth 
decade.  PD has a gradual onset and progression and it is common in 
men.  It commonly presents with rest tremor in one hand, associated 
with decreased arm swing and shoulder pain.  The disorder remains 
asymmetrical throughout  much of its course.  Other motor symptoms 
include bradykinesia, rigidity, mask like facies, impaired gait and 
balance resulting in frequent falls, freezing and motor blocks.   
The terminology parkinsonism is described by a syndrome 
characterized by a combination of six cardinal features1  
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1. Tremor at rest   
2. Bradykinesia   
3. Rigidity 
4. Loss of Postural Reflexes  
5. Flexed Posture   
6. Freezing gait.   
A combination of these signs is the basis for defining clinically 
definite, probable, possible parkinsonism. Definite parkinsonism 
requires atleast two of the above said features with one being resting 
tremor or bradykinesia. Probable parkinsonism includes resting tremor 
or bradykinesia alone and possible parkinsonism includes atleast two 
of the remaining four cardinal features. 
Non-Motor Symptoms in Parkinson’s disease 
Non-Motor symptoms are recently recognized as a major cause 
of disability in PD, contributing significantly to the decreased quality 
of life.   
The non-motor symptoms1,9 are sensory disturbances, sleep 
disorders, autonomic dysfunction, mood disorders, psychiatric 
manifestations, cognitive decline etc. Autonomic symptoms of PD 
include reduced gastrointestinal transit time with postprandial bloating 
and constipation, increased urinary frequency, urgency, urge 
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incontinence, impotence, decreased sweating and orthostatic 
hypotension.   
Cognitive and behavioral changes are common in PD.  
Attention and concentration decreases with features of executive 
dysfunction.  Global dementia occurs in 30% of patients and the 
incidence increases in frequency with the age of the patient.Anxiety, 
Depression and other mood disorders are common in PD.   
Sleep Disturbances in Parkinson’s disease 
Sleep disorders are very common in Parkinson’s disease. Sleep 
disorders comes under the “non-motor components” of PD. It can 
predate the motor manifestations of PD. Patients  may complain of 
difficulty in initiating sleep, fragmented sleep due to frequent  
awakenings in the night , early morning awakenings, inadequate night 
sleep followed by excessive daytime sleepiness (EDS), snoring, 
nightmares, hallucinations, vivid dreams, confusional arousals, panic 
attacks, periodic limb movements(PLMS), restless leg syndrome 
(RLS),REM sleep behavioural disorder etc.  
In PD, these alterations are due to various factors that affects 
the initiation, continuity, and the maintenance of sleep. The factors 
being anatomical involvement of the sleep regulating 
structures(degeneration of hypothamic neurons, pendunculo pontine 
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nucleus,locus ceruleus,midbrain raphe nucleus etc),motor 
rigidity,depression,dysautonomic symptoms and  by Anti- 
parkinsonian medications used in treating PD.Various studies indicate 
sleep disturbance ranges from 60-98%10,11. There is positive 
correlation with the disease severity, Schwab and England score, 
Unified Parkinsons Disease Rating Scale (UPDRS) part III, L-dopa 
score, rigidity and bradykinesia12.  
Sleep fragmentation is three times more common in patients 
with PD than in healthy controls (38.9% versus 12%)11. Defects are 
seen in the slow wave sleep(NREM stages III & IV), total sleep time, 
sleep latency and sleep efficiency. PD patients have more frequent 
awakenings and greater overall wake time than the controls. There is a 
relative increase in the stage I and stage II sleep.  
Treatment with dopaminergic agents produces sleep disruption 
with an increase in the number of awakenings and increase in the stage 
I sleep duration13. The sleep disruption is seen more with the higher 
dose of the medication. Around 40% of the PD patients take sleeping 
pills more than the healthy elderly contemporaries11. The nature of 
sleep disturbance in the early stages of PD is not well documented and 
the sleep disturbancesdescribed in literature are mostly in the 
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advanced stage of Parkinsons Disease.  There is a general observation 
that with advancing disease, sleep complaints become common. 
Respiratory dysfunction during sleep occurs in PD which can 
include apnea and hypopnea. Vivid dreams and nightmares are very 
common5.Sleep disorders in PD are related to primary pathological 
changes of the disease itself, arousals due to immobility, co-morbid 
primary sleep disorders, and the side effects of anti-parkinsonian 
medications.   
Sleep deprivation causes excessive day time somnolence. The 
consequences1 of EDS were impaired performance and productivity, 
impaired short-term memory, attention, concentration, judgement and 
cognition, impaired quality of life, psychological stress, increased 
morbidity and mortality (increased likelihood of accidents).Excessive 
daytime sleepiness is seen in 15-51%14 of PD patients. Factors 
contributing to excessive daytime sleepiness are motor disorders 
associated with PD, insomnia, mood and anxiety disorders, effect of 
drugs and concurrent medical illness. 
The Sleep Disturbance in PD is explained by  
1. Primary involvement of sleep regulating structures,   
2. Secondary involvement through motor, depressive and 
dysautonomic Symptoms, 
3. Tertiary involvement through pharmacologic measures. 
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Primary involvement of sleep regulating structures:   
Various anatomic structures are involved in the generation and 
maintenance of the sleep-wake cycle in human beings. The 
cortex,brainstem, thalamus, hypothalamus, limbic system, basal 
ganglia are the structures involved in the generation of sleep . The 
substrates being pedunculo pontine nucleus, lateral dorsal tegmuntum, 
dorsal midbrain raphe nucleus, locus ceruleus, tuberomamillary 
nucleus of hypothalamus, peri-aqueductal grey matter of midbrain 
etc.They undergo degeneration resulting in sleep disturbance.  
Many neurotransmitters like glutamate, gamma amino butyric 
acid, glycine, hypocretin/orexin, melanin-concentrating hormone, 
melatonin, histamine, acetylcholine, dopamine, serotonin, and 
noradrenaline are implicated in the regulation of sleep. The 
degenerative process may actually begin at a very early stage in some 
patients and at a later stage in others.  Thus, the sleep disturbance may 
vary from patient to patient and it is further influenced by concomitant 
medications or associated conditions. 
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Secondary involvement through motor, depressive and 
dysautonomic Symptoms: 
Rigidity, tremor and bradykinesia, are the cardinal features of 
PD.  These symptoms recur at night, during the lighter stages of sleep 
resulting in nocturnal akinesia which gives rise to discomfort and 
sleep disturbance.  Patients are also forced to sleep for long periods in 
the same posture, causing sensory disturbance like numbness and pain.  
Muscle cramps also causes sleep disturbance.Periodic limb 
movements (PLM) are more common in PD even in early untreated 
patients. 
Tremor may be present for 30% of time spent in bed causing 
nocturnal wakefulness.  It disappears in REM sleep and present with 
reduced amplitude in NREM sleep.  Rigidity and cog-wheeling are 
also reduced but present during sleep.  Sleep related respiratory 
muscle dysfunction is due to abnormal tone in upper airway muscles, 
incoordination of respiratory muscles, and fluctuations in muscle 
functioning.  The immediate sensation on awakening is a sensation of 
suffocation interpreted as sleep apnea6. PD patients with severe sleep 
disturbance and excessive day time sleepiness have irregular sleep-
wake pattern. As there is alteration in the circadian regulation in PD 
patients there is a change in the functioning of autonomic nervous 
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system25 .Insomnia reported in 32% of the PD patients26. The most 
common complaints by the patients are defect in the sleep initiation, 
sleep fragmentation and early awakenings. The prevalence of 
insomnia increases with age. 
Depression is the common cause of sleep disturbance in elderly. 
There is difficulty in falling asleep and remaining asleep. Early 
morning awakening is a cardinal feature seen in depression. Insomnia 
is the earliest sign of mood disturbance and it occurs before the 
clinical evidence of depression.40% of the PD patients have 
depression27. The causes of depression ranges from neurochemical 
imbalances associated with PD to the consequences of living with the 
chronic progressive degenerative illness. There is no correlation of the 
depression with age, disease duration, severity, and cognitive 
impairment. Depression in PD associated with sleep onset difficulties, 
and sleep interruptions. SSRIs are effective in treating depression in 
PD.  
Psychosis affects one fifth of the PD patients28 and causes sleep 
problems. Frequency of psychosis increases with age and it also 
correlates with cognitive impairment. Hallucinations can occur in any 
stage of PD either spontaneously or secondary to medications. Around 
40% of PD patients have hallucinations35. Hallucinations are 
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associated with RBD. Hallucinators have more ESS score. Newer 
antipsychotics like Quetiapine, arpiprazole are effective in the 
management of psychosis without aggravating the disease29. 
50% of the PD patients complains of pain30 due to foot 
dyskinesia which is related to the off state or insufficient dose of 
dopaminergic therapy. Adjustment of the dosages and analgesics 
provide relief.  
The prevalence of cognitive impairment rises with age. In a 
cohort study31, more than three quarters of the patients developed 
dementia during a 8 year study period. Early hallucinations and 
akinetic rigid phenotype are associated with increased risk of 
dementia.  
Autonomic disturbances are common in PD32. Dysphagia, 
paroxysmal sweating are specific to PD. Nocturia, day time urge 
incontinence, constipation, impotence, hypothermia are related to the 
ageing process or may be secondary to anti parkinsonian medications. 
Nocturia is the commonest symptom encountered in clinical practice. 
There is a high prevalence of nocturia in PD. 80% of the PD patients 
passes urine 2 or more times per night and 33% of them urinate more 
than three times per night33. The frequency of nocturia correlates with 
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the disease severity. In a study conducted in a group of 41 idiopathic 
PD patients, 32 had urinary symptoms in the form of increased 
frequency in 27 cases (65%), urgency in 9 cases (21%), urge 
incontinence and dysuria in 1 case34. There is an increase in urinary 
frequency when the dopaminergic medication wears off. So a long 
acting medication given at the night will be helpful.Other autonomic 
features like night time blood pressure variablity or paradoxical 
hypertension occur at later stage of the disease35. 
Tertiary Involvement through Pharmacologic Treatment 
Pharmacological treatmentinfluence the sleep in different ways, 
depending on the drug and its administration schedule.  Anti-
parkinsonian medications can both aggravate and relieve nocturnal 
symptoms.  Levodopa plays a dual role.  Low doses of levodopa have 
a sedating, sleep-enhancing effect, whereas higher doses have a 
stimulating, sleep-inhibiting effect. Respiration may be intially 
enhanced by entral levodopa stimulation and later inhibited by 
peripheral action of levodopa on chemoreceptor reflexes.  Levodopa 
may also results in night time hallucinations.  Levodopa may relieve 
night time akinesia and reduce the muscle tone in PD patients.  As the 
levodopa wears off in the early morning hours, akineticepisodes 
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occursresulting in early morning awakenings. Nightmares are reported 
in 32% of PD patients. There is a positive correlation of the 
nightmares with the staging, severity and L-dopa dosage. Reducing 
the dose of dopaminergic medications and the anti-cholinergic agents 
helps to relieve the symptoms.  
Symptoms of Sleep Disturbances in Parkinson’s disease: 
Insomnia: 
Sleep initiation insomnia is uncommon.Sleep maintenance 
insomnia has been observed before the levodopa era.  In this form of 
insomnia, the patient wakes after 2 to 3 hours feeling relatively 
refreshed and unable to sleep again. There is lack of consolidated 
sleep. The sleep remains fragmented throughout the night.  In the 
daytime, sleepiness recurs and the patient takes multiple short naps.  
Although sleep is not consolidated, the total quantity of sleep over a 
24 hour period is normal. Secondary factors may contribute including 
decreased body movements and nocturia, pain, anxiety, depression, 
vivid dreams. 
Hypersomnia: 
Excessive daytime sleepiness is defined as symptomatic 
daytime somnolence with frequent sleep periods.  Pramipexole, a non- 
ergot dopmine agonist cause drowsiness and sudden irresistible naps. 
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The sleep attacks were reduced after the discontinuation of the drug.  
Another study showed no difference between non-ergots(ropinirole 
/pramipexole) and ergots(bromocriptine/cabergolin)and it concluded 
that daytime sleepiness correlates with autonomic failure, longer 
duration or advanced stage of the disease, advanced age of the patient, 
and male sex but not with use of any specific dopaminergic 
agonist.(Ondo et al)36. 
Parasomnia: 
The most common parasomnia is the Rapid Eye Movement 
Sleep Behaviour Disorder (RBD).RBD is characterised by loss of 
REM sleep related hypotonia associated with abnormal motor 
activities and the patients may enact the dreams causing injury to 
themselves or to the bed partners.  RBD may be primary or secondary, 
most of them are due to neurodegenerative diseases like PD, MSA, 
corticobasal degeneration, DLBD, olivopontocerebellar atrophy, and 
PSP.In Narcolepsy,a degenerative disease of hypothalamus is 
characterised by REM onset sleep. 
The prevalence of rapid eye movement disorder varies from 15 
to 47%21. REM sleep behaviour disorder (RBD) predates the motor 
symptoms in PD in 52% of individuals (olson et al)7 RBD is common 
in akinetic-rigid phenotype of PD. PD patients with RBD have high 
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incidence of cognitive impairment, impaired colour discrimination, 
diminished olfaction, dysautonomia, increased prevalence of sleep 
walking behaviour, less responsive to dopa and history of frequent 
falls. Increased muscle activity in REM sleep, which is an early sign 
of RBD is reported in asymptomatic patients who have PD23. 
Individuals with RBD have significantly increased risk of developing 
parkinsonismif there is decreased nigrostriatal dopaminergic activity 
in the functional imaging over the next decade. Dopaminergic 
medications, sedatives-hypnotics/tricyclic anti-depressants, and anti-
cholinergics are reported to cause RBD24.   
Contribution of Motor Dysfunction to Sleep Disturbance in PD 
Motor disorders that appear at night in PD include tremor, 
rigidity, bradykinesia, painful dystonia, dyskinesias, periodic limb 
movements, restless legs, akathisia, REM sleep behavior disorder. 
Role of Tremor:  
EMG recording of the muscles involved in tremor during 
wakefulness shows rhythmic repetitive muscle contractions during the 
NREM sleep. The repetitive muscle contraction is considered the 
equivalent of parkinsonian tremor during sleep which contributes to 
light and fragmented sleep.  (Askenasy and Yahr)37 
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Role of Rigidity :  
Although muscle tone decreases during the different stages of 
sleep, variable degrees of rigidity can persist in parkinsonian patients 
during the night, especially those who have motor fluctuations. This 
rigidity accounts for stiffness, mainly of axial distribution, and is a 
major contributor to nocturnal pain in PD. This is responsible for poor 
nocturnal mobility that manifest as impairment in making postural 
adjustments like difficulty turning over in bed.  (Rye DB)38. 
Painful dystonia occur in the early morning, but dystonic 
spasms and postures, usually localized to the legs, can appear at any 
time during the night. The pathophysiology of nocturnal painful 
dystonia is similar to that of the off-period dystonia experienced by 
patients with motor fluctuation during the day.  Levodopa-induced 
dyskinesias are more intense in the evening, due to cumulative effect 
of the recent levodopa doses.  The alerting effect of Levodopa cause 
delayed onset of sleep.  When the patient arouse from sleep at night 
the dyskinesias reappear and prevents the patient from going back to 
sleep.  Nighttime motor manifestations is related to the deficit in the 
dopaminergic tone during the night as it well responds to the 
controlled release formulations of levodopa (Stocchie39 et al, Iranzo3 
et al). 
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RESTLESS LEG SYNDROME (RLS)  
It is the most common movement disorder, not commonly 
recognized. The diagnosis of RLS is made clinically and with the 
criteria based on International Restless Legs Syndrome Study Group 
(IRLSSG) established in 1995 (Walters, 1995) and later modified in 
2003(Allen et al., 2003).The patients has an unpleasant, uncomfortable 
sensations in the legs predominantly in the evening or night hours 
which cause an intense urge to move the legs and the movements like 
stretching, walking relieves the unpleasant sensations partially or 
completely. It may associated with a positive family history, presence 
of periodic limb movements in sleep or wakefulness and response to 
dopamine. 
The overall prevalence of RLS has been estimated at about 10% 
for all adult populations(North American and European populations) 
but appears to be much less in Asian surveys (1%-3%),suggesting 
ethnic and racial differences in RLS.Women have a greater 
prevalence, and has a gradually progressing course. Around 15% to 
20% of patients complain of pain. The movements are predominantly 
present in the evening hours and as the disease progress the 
movements may be noted in the morning also.80% of the RLS patients 
have PLMS.RLS mainly causes difficulty in sleep initiation. 
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Neurological examination is usually normal in the idiopathic form of 
Restless leg syndrome. 
It is proposed that dopaminergic nerve cell loss in the striatum 
is involved in the generation of PLMs in patients with PD1. Recent 
hypothesis states that reduced dopamine cellular function secondary to 
local iron deficiency is the pathophysiology behind RLS.Iron is an 
essential cofactor for tyrosine hydroxylase, the rate-limiting enzyme 
involved in dopamine synthesis, and iron deficiency decreases the 
number of dopamine D2 receptor binding sites, so the current research 
focus is centred on iron-dopamine dysfunction. Meta analysis of 
various studies showed the site of CNS involvement in RLS is the 
brain stem, but the spinal cord may be one of the probable site.  
This disorder increases in prevalence with age and it is seen in 
15% of the elderly patients. This movement causes frequent 
awakenings and arousals, thereby disrupting the sleep. 20.8% of the 
PD patients have RLS, which is twice that of the control population20. 
Ondo and his co-workers stated that PD preceded the development of 
RLS in 68% of the patients. They have also reported that RLS is not 
associated with high ESS score20. 
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PERIODIC LIMB MOVEMENTS IN SLEEP 
PLMS are stereotyped limb movements, present in the NREM 
sleep characterised by dorsiflexion movements of the ankle and   
flexion movements of the knee and hip for a period of 0.5 to 10 
seconds with an average interval of 20 to 40 seconds and atleast 4 
consecutive movements should be present. 
PLMS is seen in at least 80% of patients with restless legs 
syndrome. PLMS occurs most commonly in RLS but may also occur 
in a large number of other medical, neurological, and sleep disorders 
and with medications like (e.g. SSRIs, tricyclic antidepressants) and 
even in normal individuals, particularly in those older than 65 years. 
PLMS without associated RLS cause repeated awakenings during 
sleep. There is also a growing body of evidence that PLMS may 
simply be a PSG observation and does not have any clinical 
significance.  
PD patients show increase periodic limb movements (PLM) 
during REM and NREM sleep than the healthy controls. 15% of the 
PD patients had PLMs in a study done by Arnulf and his associates19 
and they concluded that there is no correlation between the PLM and 
EDSS score. 
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SCALES USED TO ASSESS SLEEP DYSFUNCTION IN PD  
Studies on sleep disorders are conducted with questionnaire 
based scales that asses the subjective sleep disturbance and by PSG 
which objectively measures sleep. Common questionnaire used were 
PDSS, SCOPA-SLEEP, Epworth sleepiness scale(ESS).Cut off points 
taken to identify patients of PD with sleep disturbance were 82 for 
PDSS and 6 for SCOPA-S NS (night time sleep). (Martinez-Martin et 
al,)40. Studies have compared PDSS to SCOPA and found that both 
scales were reliable, valid and useful means to evaluate sleep disorders 
in PD.PDSS predominantly evaluate nocturnal sleep disturbances 
whereas SCOPA-S assesses nocturnal sleep disorders and daytime 
somnolence to a similar extent (Martinez-Martin et al)40. 
On comparing with the controls, PD patients had excessive 
daytime somnolence compared to controls (43 vs 10%), and similarly 
had excessive nighttime sleep problems (27 vs. 9%), or used sleep 
medications (17 vs 12%).  In PD patients, depressive symptoms were 
a major contributor to nocturnal sleep problems.  The nocturnal sleep 
problems were related to dopamine-agonist and levodopa dose, 
whereas daytime somnolence was related to age, dopamine-agonist 
dose, and disease severity. (Verbaan et al,)41 
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POLYSOMNOGRAPHY (PSG) FINDINGS IN PD:  
Patients with PD have decreased total sleep time and frequent 
awakenings. Stage 2 NREM sleep show reduction in the sleep spindles 
and K complexes. Slow wave sleep (Stage 3 and Stage 4) is decreased.  
REM sleep shows increased alpha activity and it was hypothesized 
that it was due to early disconnection between generators of REM and 
NREM sleep in PD.It is debated whether REM sleep percentage is 
normal or reduced. Electromyographic atonia is periodically abolished 
in REM sleep. Repetitive blinking is seen in the beginning of the 
recording and blepharospasm is seen during slow wave sleep before 
the REM sleep episodes. Polysomnography has revolutionized the 
sleep assessment in PD.   
SLEEP STUDIES IN PD 
Studies have compared the subjective sleep perception against 
objective parameters obtained from polysomnography and there are 
also studies relating the loss of physiological sleep architecture and 
sleep fragmentation in relation to the severity of the disease process. 
Happe42 et al, compared the sleep parameters in parkinson’s 
disease patients with the healthy elderly controls.  The patients with 
PD showed reduced subjective sleep decreased sleep duration, reduced 
sleep efficiency compared with controls.  The author concluded that 
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PD patients have objectively and subjectively disturbed sleep as 
compared to the healthy controls of  same age group. 
Diederich43 et al, have made a correlation analysis of the sleep 
parameters with the disease duration.The sleep latency correlates 
directly with the disease duration.The total sleep time, deep sleep 
time, REM sleep time and sleep efficiency correlated inversely with 
the disease duration.  It was concluded that in PD nocturnal sleep 
destructuring is related to the disease duration and it is independent of 
other major disease parameters. 
Norlinah et al44, in his study showed sleep fragmentation, 
periodic limb movement and sleep related breathing disorder 
correlates with the higher UPDRS course.  The total sleep time and the 
sleep efficiency correlates poorly with the UPDRS scores.   
Young et al45, made a comparison of sleep disorders in mild vs 
Severe PD.  Patients with  mild (Hoehn and Yahr stage 1 or 2) and 
severe (Hoehn and Yahr stage 4 or 5) idiopathic Parkinsons’s disease  
were recruited and underwent overnight polysomnography, autonomic 
function testing and assessed with questionnaire addressing their 
quality of life, mood, and drug dosages. Both groups slept poorly.  
Their sleep efficiency was decreased, and the architecture was 
fragmented.  There was a significant increase in the number of voids 
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overnight in the severe disease group. It was concluded that the 
severity of Parkinson’s disease didn’t correlate  with the change in the 
measured sleep parameters and other parameters like drug plays a 
major role in sleep disturbance. The motor/functional measures of 
disease severity correlates poorly with the sleep disturbance.  Nocturia 
is an important factor which disturbs sleep, particularly in the severe 
disease group. 
Kumar et al46 assessed daytime sleepiness in patients with 
Parkinson’s disease using the Epworth Sleepiness Scale (ESS).  
Patients with PD (n=49) and age matched controls (n=115) from 
movement disorders clinic of the All India Institute of Medical 
Science in New Delhi were evaluated.  An ESS score of >8 was 
considered abnormal.  The author concluded that higher Hoehn and 
Yahr staging and higher Unified Parkinson’s Disease Rating Score 
was associated with excessive day time sleep as assessed by ESS and 
the sleep disturbance is more common patients with PD than the 
controls (P < 0.001). 
The review of literature has revealed extensive knowledge 
about the sleep dysfunction in PD.  We made an attempt to evaluate 
the subjective and objective sleep disturbance of Idiopathic 
parkinson’s disease patients in our institute. 
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MATERIALS AND METHODS 
STUDY DESIGN:   Cross sectional study 
STUDY SITE: This study was carried out in the Department of 
Neurology, Madras Institute of Neurology, Chennai. 
STUDY PERIOD: December 2011 to December 2012. 
INCLUSION CRITERIA: 
 Patients who fulfill the “UK Parkinson’s Disease Society- Brain 
Bank Clinical Diagnostic Criteria” admitted in neurology 
ward/consulting in Neurology outpatient clinic in Rajiv Gandhi 
Government General Hospital. 
EXCLUSION CRITERIA: 
Patients who are bedridden associated with co-morbidities which 
affects the sleep like uncontrolled diabetes, LV dysfunction, 
Bronchial Asthma, Chronic obstructive Pulmonary disease, vascular 
Parkinsonism, head injury, dementia, Parkinson plus syndromes. 
METHODS AND ANALYSIS: 
1)Detailed history and neurological examination  
2)Assessment of severity of Parkinsons disease using Unified 
Parkinsons Disease Rating Scale(UPDRS). 
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3)Sleep  assessment using Parkinsons disease sleepiness scale(PDSS) 
and Epworth Sleepiness Scale(ESS) 
4)Polysomnography. 
SAMPLE SIZE: 
50 patients suffering from Idiopathic Parkinsons Disease  
STASTITICAL DATA ANALYSIS: 
Pearson’s Correlation Analysis and logistic regression, SPSS16 
PARKINSONS DISEASE SEVERITY QUESTIONNAIRE 
INSTRUMENTS: 
1)Modified Hoen and Yahr staging 
2)UPDRS 
SLEEP QUESTIONNAIRE INSTRUMENTS: 
1)Parkinsons disease sleep scale(PDSS) 
2)Epworth sleepiness scale(ESS) 
POLYSOMNOGRAPHY RECORDING: 
Patients with idiopathic pakinson’s disease were subjected to 
overnight polysomnographic study using  parameters like EOG, EEG, 
EMG,ECG,Oxygen saturation, Respiratory effort, air flow, body 
position. 
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Parts of Polysomnography (PSG) 
 
Nocturnal Polysomnography 
 
 
           Hair wash /Avoid afternoon nap/Stop nonessential medications 
 
EEG, EOG, EMG(Chin,Tibial), ECG, Airflowmeter, Pulseoximeter,          
Respiratory effort, snoring,  body position. 
 
Scoring of Sleep Study 
The participants underwent overnight polysomnography which 
includes electroencephalogram to score sleep, an electromyogram on 
the chin and right anterior tibialis muscle, an electrooculogram to 
record eye movements, electrocardiogram, a nasal airflow sensor, 
chest and abdomen belts, a pulseoximeter, a snore microphone and 
body sensors.  
Total sleep time (TST), sleep efficiency, sleep latency, sleep 
stages, arousals, snore indices and respiratory events were scored.  
The scoring of sleep was done according to the rules and technical 
specifications given by AASM Manual for the scoring of sleep and  
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associated events.  An Epoch is a 30 second sequence, and throughout 
the study, sleep is scored in 30 second sequential epochs. 
Stage W (Wakefulness) is defined as alpha rhythm 8 -13 HZ 
activity recorded over the occipital region with eyes closed attenuating 
with eye opening, eye blink, reading and rapid eye movements seen. 
Stage 1 (N1) comprises 3 to 8% of sleep.  The features being 
alpha wave mixed with theta wave with few beta waves, slow rolling 
of eyeballs, vertex waves with duration less than 0.5 seconds 
maximally seen over the central region and positive occipital sharp 
transient waves  
Stage 2 (N2) comprises 45 to 55% of sleep.  The features being 
predominantly theta waves and 20% delta waves.  K complex and the 
sleep spindles are seen in this stage. K complex is a well defined 
negative sharp wave immediately followed by a positive component 
standing out from the background EEG with total duration more than 
0.5 sec maximally seen in the frontal region.  The sleep spindles are 
trains of distinct waves with frequency 11-16 Hz maximally seen in 
the central leads. 
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Stage 3 and 4 (N3) also called slow wave sleep with 20 to 50% 
of delta wave seen in stage 3 and more than 50% delta wave seen in 
stage 4.  There will be no eye movements and the EMG shows 
hypotonia. 
Stage R (REM Sleep) characterized by rapid eye movement 
which are conjugate irregular sharply peaked eye movements with an 
initial deflection lasting less than 500 msec.  EEG shows low voltage 
irregular theta and delta activity, saw tooth waves.  EMG shows 
hypotonia or atonia. 
Sinus tachycardia was scored during sleep for a sustained sinus 
heart rate greater than 90 beats per minute for adults and bradycardia 
during sleep for a sustained heart rate of less than 40/min.  Cardiac  
asystole for a  pause more than 3 sec.   
While scoring Periodic Leg Movements (PLMs) the minimum 
duration of a LM event is 0.5 sec and max is 10 sec.  The minimum 
amplitude elevation was 8 µ V above the resting EMG.  The LM stops 
when the variability from baseline resting EMG is ≤  2 µ V. 
REM sleep Behaviour Disorder (RBD) was defined as sustained 
tonic muscle activity in REM sleep i.e, an epoch of REM sleep with at 
least 50% of the duration of the epoch having a chin EMG amplitude, 
greater than the minimum amplitude in NREM.   
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The patients for our study were recruited from the Neurological 
services.  The number of patients recruited were 50 members.All of 
them underwent sleep assessment using standard questionnaire and 
overnight polysomnography.  
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RESULTS 
 
Fifty patients of Idiopathic Parkinson’s disease were recruited 
based on United Kingdom Parkinson’s Disease Society brain bank 
Criteria for the sleep study. All of them underwent clinical assessment. 
Their staging and severity was scored using Hoehn and Yahr staging 
system and Unified Parkinsons Disease Rating Scale part III 
respectively.  
 
Subjective sleep disturbance was assessed using standard sleep 
related questionnaire (Parkinsons Disease sleepiness scale). They were 
asked about their nature of sleep disturbance. Disturbed sleep was 
reported by 35 patients. Of them 30 have difficulty   in falling sleep 
and 24 have difficulty in maintaining the sleep due to frequent 
awakenings. Most of the patients told that they woke up in the night 
mainly for passing urine. Objective sleep analysis was done using 
overnight polysomnography. The day time disturbance was assessed 
using Epworth sleepiness scale. ESS Score more than ten was 
considered significant. Day time somnolence was reported by 15 
patients. 
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DEMOGRAPHIC PROFILE 
SEX 
 Frequency Percent Valid Percent Percent 
 
FEMALE 15 30.0 30.0 30.0 
MALE 35 70.0 70.0 100.0 
Total 50 100.0 100.0  
 
 
The study participants were 35 (70%)males and 15 
(30%)females with the age group ranges from 46 to 70 years(mean 
age is 57.16 years).Females belong to the age group between 48 to 70 
years(mean age 59.73years) and age range in the males lie between 46 
to 70 years(mean age 56.05 years). 
Series 1
MALE
35
70%
Series 1
FEMALE
15
30%
SEX
35 
 
AGE 
  Descriptive Statistics  
 
Number Minimum Maximum Mean 
 AGE 50 46.00 70.00 57.1600 
MALE 35 46 70 56.05 
FEMALE 15 48 70 59.3 
 
 
DURATION 
  Descriptive Statistics   
 
N Minimum Maximum Mean Std. Deviation 
DURATION 50 1.00 12.00 5.3000 2.29463 
 
The duration of the disease ranges from 1 year up to 12 years with the 
mean duration of 5.3 years. More than 50% (n=26) of the patients the 
duration of the disease was between five to ten years. The duration 
was more than 10 years in four of the patients. 
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STAGING (Hoehn and Yahr) 
  Descriptive Statistics   
 N Minimum Maximum Mean 
Std. 
Deviation 
STAGING 50 1.00 5.00 2.9100 .80616 
 
 
 
 
 
 
 
 
 
 
 
Most of the patients (n=40) had a Hoehn and Yahr score of 3 or 
less. Only 20% (n=10) of the patients had a score of >3. Eight   
patients comes under stage 4 and two patients comes under stage 5. 
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SEVERITY 
The severity of the disease assessed using UPDRS motor score. 
It ranges between minimum score of 10 and a maximum score of 40, 
the mean value is 25.3. 
  Descriptive Statistics   
 N Minimum Maximum Mean 
Std. 
Deviation 
SEVERITY 50 10.00 40.00 25.3600 7.23585 
 
CORRELATION ANALYSIS 
        CORRELATION ANALYSIS DURATION STAGING 
 
SEVERITY 
Pearson Correlation 
.903** .872**  
Sig. (2-tailed) 
<0.05 <0.05
N 50 50
 
The severity of the disease when correlated with the disease duration 
and Hoehn and Yahr staging showed a significant positive correlation 
(p<0.05). 
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PARKINSONS DISEASE SLEEPINESS SCORE (PDSS) 
There are 15 questions which rates the sleep based on the 
experience during the past week .For each question the minimum 
score is zero and the maximum score is ten. Score 150 is maximum 
normal score. In our study the PDSS score ranges from 80 to 150 with 
the mean value of 115.90. 
  Descriptive Statistics  
 N Minimum Maximum Mean 
Std. 
Deviation 
PDSS 50 80.00 150.00 115.90 22.02804 
 
CORRELATION ANALYSIS 
 DURATION STAGING SEVERITY 
PDSS 
Pearson Correlation -.831** -.826** -.955** 
Sig. (2-tailed) <0.05 <0.05 <0.05 
 N 50 50 50 
 
The subjective sleep assessment using PDSS score correlates 
positively with the duration of the disease, staging and the severity of 
the disease (ie)with progression of the disease there is a significant 
drop in the PDSS score. 
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EPWORTH SLEEPINESS SCORE (ESS) 
ESS  assess the chance of   falling   asleep in the morning. It 
carries 8 questions, each questions carries a score of zero to three. A 
score of > 10 is considered abnormal. Day time somnolence was 
reported by 15 patients and it is predominantly seen in  whom, the 
duration of the disease is more and  the staging and the severity of the 
disease were in  higher range. 
 
  Descriptive Statistics   
 N Minimum Maximum Mean 
Std. 
Deviation 
ESS 50 .00 16.00 5.8600 5.42861 
 
In our study the ESS score ranges from zero to sixteen with a 
mean value of 5.86. 
POLYSOMNOGRAPHY ANALYSIS 
TOTAL SLEEP TIME 
The total sleep time ranges from 210 (3hr 30min)minutes to 
445( 7hr 25min) minutes with the mean value of 310(5hr10 min).Total 
sleep time is reduced in 40 patients.(80%) 
 N Minimum Maximum Mean 
Std. 
Deviation 
TSTmin      50 210.00 445.00 310.30 45.812
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Correlation of the total sleep time with the duration, staging, severity, 
PDSS Score, showed strong positive correlation.(p<0.05).The total 
sleep time is significantly reduced as the disease progress and higher 
the staging and severity of the disease. 
  DURATION STAGING SEVERITY PDSS 
TSTmin Pearson Correlation -.762** -.745** -.748** .738**
Sig. (2-tailed) 
<0.05 <0.05 <0.05 <0.05 
N 50 50 50 50 
 
Latency of sleep 
It is the time taken to fall asleep after going to the bed. The normal 
latency of sleep is 15 to 20min.The range of this parameter in our 
study is between 2 minutes to 50 minutes with the mean value of 22.3 
minutes. 
  
Descriptive 
Statistics   
 N Minimum Maximum Mean 
Std. 
Deviation 
LATENCY 50 2.00 50.00 22.3600 11.45846 
 
Prolongation of latency of sleep indicates defect in the initiation of 
sleep. Latency is prolonged in 26 patients (>50%). 
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Sleep efficiency: 
Sleep efficiency is ratio of number of hours slept divided by number 
of hours spent in the bed. The normal sleep efficiency is> 85% which 
is seen only in 12 of our patients. The sleep efficiency ranges between   
55%  to 94% in our study with a mean value of 72.9%. 
Descriptive Statistics
N Minimum Maximum Mean Std. Deviation 
EFFICIENCY 50 55.00 94.00 72.9000 9.55809 
 
                                         STAGES OF SLEEP 
There is a significant increase in the N1N2 stages of  NREM sleep 
associated with a decrease in the slow wave sleep(N3) in 80% of our 
study group (p value <0.05) 
No. NI N2 STAGE N3 STAGE PERCENTAGE
 40 PATIENTS Increased Decreased 80% 
10 PATIENTS Normal Normal 20% 
 
 B S.E. Wald df Sig. Exp(B) 
Constant -1.386 .354 15.374 1 <0.05 .250 
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REM SLEEP 
Among the 50 patients, 10 patients in our study group had 3 
Rapid Eye Movement  sleep episodes , 37 patients had 2 REM sleep 
episodes  and 3 patients had only 1 REM sleep stage. The overall 
duration of REM sleep in the total sleep time is reduced and REM 
sleep onset latency is also prolonged (>2 hours) in 80% (n=40) of our 
patients. 
REM sleep behavioural disorder (RBD) was seen in 10 of our 
patients (20%) and it showed no correlation with duration, staging, 
severity of the disease and the sleep scores. 
Periodic Limb Movements in sleep (PLMS) 
These repetitive stereotyped movements present in NREM sleep 
were seen in 15 of our patients. It is scored as PLMS index. It is 
expressed as number of PLMS per hour of sleep. The upper limit of 
the normal PLMS index is five. As per our correlation analysis, the 
frequency of the periodic leg movements increases with the   increase 
in the duration of the disease and higher the staging and severity of the 
disease. 
Pearsons correlation analysis shows significant positive 
correlation (p value <0.005) of PLMS with disease parameters like 
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duration, staging, severity of the disease and sleep scores like PDSS 
and Epworth sleepiness score 
A maximum number of 8 patients in stage 4 had PLMS, 2 
patients in stage 5 and 3 patients in stage 3 had PLMS. 
 
 
 
 
 
 
 
 
 
 
 
CORRELATION ANALYSIS OF PLMS WITH DISEASE 
PARAMETERS: 
  DURATION STAGING SEVERITY PDSS TSTmin MAIN 
PLMS 
Pearson 
Correlation .557** .647** .506** -.561** -.498** -.412** 
 Sig (2 tailed) <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 
 N 50 50 50 50 50 50 
 
44 
 
RESTLESS LEG SYNDROME 
RLS was seen in 10 patients (20%), 4 of them were female. All 
the patients in our study having RLS had PLMS (100%). Sleep latency 
is prolonged in nine  of the ten patients  having RLS. Presence of   
RLS   correlates significantly with the duration of the disease and the 
disease severity and staging . 
APNOEA-HYPOPNEA INDEX  
Documented Apnoeic and hypopneic spells were noted in 21 
patients in our study. Classification of severity of Sleep Disordered 
Breathing (SDB) is based on AHI scoring. AHI score<5 is normal; 5- 
15 is mild SDB; 15 – 30 is moderate SDB, >30 is severe SDB .The 
distribution of AHI index ranges between 0 to 20 with the mean value 
of  3.66. AHI index didn’t show a significant correlation with the 
disease parameters   in correlation   analysis (p value >0.05) 
  DURATION STAGING SEVERITY PDSS TSTmin MAIN 
AHI 
Pearson 
Correlation .043 .167 .221 -.260 -.071 -.091 
 
Sig(2-
tailed) .766 .247 .123 .068 .625 .528
 N 50 50 50 50 50 50 
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SNORING 
Snoring is expressed as snore index, which is the number of 
snore events per hour. Snoring was seen in 14 patients and it showed 
significant correlation with the Epworth sleepiness score and PDSS 
Score. (p value <0.05) 
  SCORE df Sig 
SNORING PDSS 
4.008 1 .045   
 ESS 9.635 1 .002 
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DISCUSSION 
Sleep disorders are common in Parkinson’s disease(PD). 
Nocturnal sleep disturbance and excessive day time somnolence are 
more frequent in patients with PD than the healthy controls. The 
prevalence and the pattern of sleep disturbance is evaluated through 
this study. The study group consists of 50 patients with age group 
ranging between 46 to 70 years with varying duration, staging (based 
on Hoehn & Yahr staging) and severity (based on UPDRS Part III 
motor score).Their sleep related issues were assessed with standard 
sleep questionnaire and objective assessment was done using 
polysomnography recording. 
Evaluation with sleep questionnaire 
Patients with PD were evaluated with Parkinson’s disease 
sleepiness scale and Epworth sleepiness scale. An ESS score of more 
than 10 is considered significant. Their subjective sleep quality scores 
and daytime somnolence scores were noted. Reduced sleep quality 
were noted in 70% of our patients and excessive day time somnolence 
was reported in 30% of our patients indicating more of nocturnal sleep 
disturbance which  is in contradiction to the study done  by Verban et 
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al41 stating that excessive day time somnolence (43% Vs 10% 
controls) was more common than nocturnal sleep disturbance in PD. 
We correlated the PDSS Score and ESS score with the disease 
parameters and it correlated positively with the disease duration, 
higher staging and severity of the disease (p< 0.05).Our observation is 
similar to the results of the study done by Kumar et al46 showing 
excessive day time somnolence in PD patients when compared to the 
age matched controls and showed a positive correlation with the 
higher H &Y staging and higher UPDRS score. A similar study done 
by Perez-cloret et al47 showing that PD severity and depression scores 
correlate significantly with the diminished nocturnal sleep and 
excessive daytime sleepiness. 
This implies that neuronal degeneration in the motor areas and 
sleep centres progress simultaneously,as the sleep disorders parallels 
with the disease progression(young et al)45 
SLEEP PARAMETERS 
TOTAL SLEEP TIME 
Total sleep time is reduced in 40 patients (80%) in our study. 
The total sleep time ranges from 210 (3hr 30min) minutes to 445 
minutes (7hr 25 min) with a mean value of 310 minutes (5hr 
10min).The reduction in the total sleep time strongly correlates 
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positively with the disease duration, severity and staging of the 
disease. The observation is similar to the study done by Diederich NJ 
et al54, in which he concluded that the total sleep time, deep sleep 
time, REM sleep time and sleep efficiency (SE) were inversely 
correlated with disease duration and severity. A similar observation of 
reduction in the total sleep time in Parkinsons Disease was seen in the 
study done by Dhawan et al55. 
 
SLEEP LATENCY 
The latency of sleep is prolonged in 26 patients (52%) with a 
maximum latency upto 50 minutes and with a mean latency duration 
of 22.36 minutes. The other investigators also observed prolongation 
of sleep latency in PD patients upto 30.7 minutes (Kaynak et al, 
2005)50 and 32.6 min (Wetter et al)47. The latency of sleep in PD is 
prolonged than the normal healthy elderly individuals who tends to 
fall asleep within the normal 20 minutes (Boselli et al)49. 
 
SLEEP EFFICIENCY 
The normal sleep efficiency is> 85% which is seen only in 12 of 
our patients. Sleep efficiency is reduced in 38 patients (76%) which is 
higher than the previous studies which showed reduced sleep 
efficiency between 69.2 + 17.0 (Wetter et al,2000)48. This sleep 
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efficiency in PD patients was much less than the normal healthy 
individuals (Boselli et al)49. 
STAGES OF SLEEP 
Sleep in polysomnography is divided into 4 stages [stage 1 
(N1)/ stage 2 (N2)/ stage 3 &4 (N3) / REM sleep].The time spent in 
N1 N2 stages of sleep increased in 40 (80%) of our patients and deep 
sleep and REM sleep were decreased in 40 (80%) of our patients.This  
results showed significant impact of the disease process with the sleep 
stages. Our findings correlate with the study done by Askenasky, 
Aldich , and Avidan  51 showing that lighter stages of sleep increase 
and slow wave sleep and REM sleep decreases in PD. 
 
RBD (REM SLEEP BEHAVIOURAL DISORDER) 
RBD is the loss of tone in REM sleep associated with acting out 
of dreams resulting in violent movements of the limbs associated with 
injury to self or the partner. In our study, RBD is seen in ten patients 
(20%) and it showed no correlation with the disease parameters 
whereas Gagnon etal53 reported that 33 patients of PD with the mean 
age group of 68.7 + 7.7 years with the mean disease duration of 7.7 +5 
had RBD 33 % with REM muscle atonia in 58% of the patients.  
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PLMS (PERIODIC LIMB MOVEMENTS IN SLEEP) 
PLMS is a significant non-motor disorder in PD causing sleep 
disturbance. PLMS is expressed as PLMS index. It is the number of 
events in one hour. PLMS score of >5 is considered abnormal. Our 
study showed PLMS in 18 patients (36%). Other studies showed 
PLMS of 22.02 + 3.6 (kaynaket al)49 and 55.4 + 3.47 (Wetter et al)47. 
PLMS is associated with arousal and contribute to significant 
nocturnal sleep disturbance. It is significantly higher than normal 
healthy age matched controls (Wetter et al, 2000)47. PLMS 
significantly correlates with the staging, severity,duration of disease 
and sleep scores.  
RESTLESS LEG SYNDROME  
10 of our patients have RLS. All the patients in our study 
having RLS had PLMS (100%).Around 9 patients   having RLS were 
found to have prolonged sleep latency. RLS also correlates 
significantly with the duration of the disease and the disease severity 
and staging , and the sleep scores. Ondo and his colleagues in their 
study showed that 20.8% of the PD patients have RLS which is twice 
that of the normal control population .Thus the prevalence of RLS in 
our study is similar to the  study reported by Ondo. 
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SLEEP DISORDERED BREATHING (SDB) 
SDB are apnoea/hypopnea and the etiology may be obstructive, 
central or mixed. Classification of severity of SDB is based on AHI 
scoring. AHI score<5 is normal; 5- 15 is mild SDB; 15 – 30 is 
moderate SDB, >30 is severe SDB. AHI>5 is taken into consideration. 
The most common type of SDB is the obstructive sleep apnoea 
(Arnulfetal, 2002)52.  In our study, obstructive sleep apnoea was seen 
in 21 out of 50 (42%) patients with AHI >5. The AHI score didn’t 
correlate with the disease duration, severity, staging and the sleep 
scores, Whereas a study done by Arnulf et al52 showed a positive 
correlation of AHI score with the advancement of PD.  
Snoring is expressed as snore index, which is the number of 
snore events per hour. In the present study, the snoring was observed 
in 14 patients (28%) which showed a significant correlation with the 
ESS score and PDSS score. Snoring is mainly due to impaired upper 
airway dynamics in PD.  
Based on the results of our study it is very clear that as the 
disease progresses in severity and as the disability due to the disease 
increases there is a proportionate decrease in the normal sleep pattern 
in the patients. Sleep is thus directly and strongly correlated with the 
disease process. Some of the previous studies proposed that sleep and 
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the motor centres are differently affected in PD and the rate of 
degeneration of one is different from the other and hence  they 
concluded that, sleep parameters doesn’t correlate with the motor 
severity. But our study clearly showed that except certain parameters, 
most of the variables correlate significantly with the disease severity 
and the disability scores. Hence, both the sleep and motor centres are 
involved in PD and degeneration of both the centres occur parallel to 
each other at a varying pace.  
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CONCLUSION 
1. Sleep disturbance occurred in 80% of the patients with Idiopathic 
Parkinson’s disease.  
2.  Total sleep time is significantly decreased in patients with   
increased severity, staging and duration of the disease.  
3.  There is a significant prolongation in the sleep latency and the 
sleep efficiency is also markedly diminished.  
4.  Patients spent less time in slow wave sleep (N3) and there is 
significant prolongation of N1/N2 stages of sleep.  
5.  The mean REM sleep duration is also reduced.  
6.  REM sleep behaviour disorder is seen in 20% of the patients 
which did not correlate with the disease parameters.  
7. Periodic limb movements in sleep is noted in 36% of patients and 
Restless leg syndrome is noted in 20% of our patients. They 
showed a significant positive correlation with the progression of 
the disease and higher staging and severity. 
8.  Sleep disordered breathing is noted in 42% of the patients which 
did not correlate with the disease parameters and sleep scores. 
9.  Snoring is noted in 28% of patients and it correlated well with the 
Epworth sleepiness score.  
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Sleep architecture is markedly affected in patients with 
Parkinson’s disease. The latency of sleep is prolonged causing 
difficulty in falling asleep. The sleep efficiency is grossly diminished 
as there is defect in the maintenance of sleep due to frequent 
awakenings. Periodic limb movements in sleep, restless leg syndrome, 
and obstructive sleep apnoea also contribute to the sleep fragmentation 
resulting in defective day time functioning. It is essential that all the 
patients with Parkinson’s disease should be evaluated for sleep 
disorders so that appropriate intervention can be taken to improve their 
quality of life. 
.  
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PROFORMA 
 
Name  ...................................................... ..... Age/sex _________    
 
Address ................................................... .......................................  
 
Disease Duration:   .................................. .......................................  
 
Currently using Drugs: ........................... .......................................  
 
 
 
1) Idiopathic Parkinsons disease     Yes / No 
        (based on BB criteria) 
 
2) Modified  Hoehn and Yahr  Staging   _________________ 
 
3) Unified Parkinson's Disease Rating Scale (UPDRS) part III  
  Score ………….. 
 
4) Sleep  related  questionnaire (score) 
1) PDSS ………………..    
 (PDSS Sub scores …….          2) ESS ……………….. 
 ……………………….) 
 
COMORBID ILLNESS Yes No 
Asthma / COPD   
Seizures   
Diabetes   
Hypertension   
Heart Disease   
Stroke   
Chronic Kidney Disease   
Depression   
Psychiatric problems   
Nasal sinus problems 
 
 
UK PARKINSON’S DISEASE SOCIETY BRAIN BANK 
CLINICAL DIAGNOSTIC CRITERIA 
 
Step 1. Diagnosis of Parkinsonian Syndrome 
 
• Bradykinesia 
• At least one of the following 
o Muscular rigidity 
o 4-6 Hz rest tremor 
o postural instability not caused by primary visual, vestibular, 
cerebellar, or proprioceptive 
dysfunction 
 
Step 2 Exclusion criteria for Parkinson’s disease 
 
• history of repeated strokes with stepwise progression of parkinsonian 
features 
• history of repeated head injury 
• history of definite encephalitis 
• oculogyric crises 
• neuroleptic treatment at onset of symptoms 
• more than one affected relative 
• sustained remission 
• strictly unilateral features after 3 years 
• supranuclear gaze palsy 
• cerebellar signs 
• early severe autonomic involvement 
• early severe dementia with disturbances of memory, language, and 
praxis 
• Babinski sign 
• presence of cerebral tumor or communication hydrocephalus on 
imaging study 
• negative response to large doses of levodopa in absence of 
malabsorption 
• MPTP exposure 
 
 
 
Step 3 supportive prospective positive criteria for Parkinson’s 
disease 
Three or more required for diagnosis of definite Parkinson’s disease in 
combination with step one 
• Unilateral onset 
• Rest tremor present 
• Progressive disorder 
• Persistent asymmetry affecting side of onset most 
• Excellent response (70-100%) to levodopa 
• Severe levodopa-induced chorea 
• Levodopa response for 5 years or more 
• Clinical course of ten years or more 
 
MODIFIED HOEHN AND YAHR STAGING 
STAGE 0 = No signs of disease. 
STAGE 1 = Unilateral disease. 
STAGE 1.5 = Unilateral plus axial involvement. 
STAGE 2 = Bilateral disease, without impairment of balance. 
STAGE 2.5 = Mild bilateral disease, with recovery on pull test. 
STAGE 3 = Mild to moderate bilateral disease; some postural          
instability; physically independent. 
STAGE 4 = Severe disability; still able to walk or stand unassisted. 
STAGE 5 = Wheelchair bound or bedridden unless aided 
 
 
UNIFIED PARKINSON'S DISEASE RATING SCALE (UPDRS) 
III. MOTOR EXAMINATION 
18. Speech 
0 = Normal. 
1 = Slight loss of expression, diction and/or volume. 
2 = Monotone, slurred but understandable; moderately impaired. 
3 = Marked impairment, difficult to understand. 
4 = Unintelligible. 
19. Facial Expression 
0 = Normal. 
1 = Minimal hypomimia, could be normal "Poker Face". 
2 = Slight but definitely abnormal diminution of facial expression. 
3 = Moderate hypomimia; lips parted some of the time. 
4 = Masked or fixed facies with severe or complete loss of facial 
expression; 
lips parted 1/4 inch or more. 
20. Tremor at rest (head, upper and lower extremities) 
0 = Absent. 
1 = Slight and infrequently present. 
2 = Mild in amplitude and persistent. Or moderate in amplitude, but 
only intermittently present. 
3 = Moderate in amplitude and present most of the time. 
4 = Marked in amplitude and present most of the time. 
21. Action or Postural Tremor of hands 
0 = Absent. 
1 = Slight; present with action. 
2 = Moderate in amplitude, present with action. 
3 = Moderate in amplitude with posture holding as well as action. 
4 = Marked in amplitude; interferes with feeding. 
22. Rigidity (Judged on passive movement of major joints with 
patient relaxed in sitting position. 
Cogwheeling to be ignored.) 
0 = Absent. 
1 = Slight or detectable only when activated by mirror or other 
movements. 
2 = Mild to moderate. 
3 = Marked, but full range of motion easily achieved. 
4 = Severe, range of motion achieved with difficulty. 
 
 
23. Finger Taps (Patient taps thumb with index finger in rapid 
succession.) 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have 
occasional arrests in movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or 
arrests in ongoing movement. 
4 = Can barely perform the task. 
 
24. Hand Movements (Patient opens and closes hands in rapid 
succesion.) 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have 
occasional arrests in movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or 
arrests in ongoing movement. 
4 = Can barely perform the task. 
25. Rapid Alternating Movements of Hands (Pronation-supination 
movements of hands, vertically and 
horizontally, with as large an amplitude as possible, both hands 
simultaneously.) 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have 
occasional arrests in movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or 
arrests in ongoing movement. 
4 = Can barely perform the task. 
26. Leg Agility (Patient taps heel on the ground in rapid succession 
picking up entire leg. Amplitude 
should be at least 3 inches.) 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have 
occasional arrests in movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or 
arrests in ongoing movement. 
4 = Can barely perform the task. 
 
 
27. Arising from Chair(Patient attempts to rise from a straightbacked 
chair, with arms folded across chest.) 
0 = Normal. 
1 = Slow; or may need more than one attempt. 
2 = Pushes self up from arms of seat. 
3 = Tends to fall back and may have to try more than one time, but can 
get up without help. 
4 = Unable to arise without help. 
28. Posture 
0 = Normal erect. 
1 = Not quite erect, slightly stooped posture; could be normal for older 
person. 
2 = Moderately stooped posture, definitely abnormal; can be slightly 
leaning to one side. 
3 = Severely stooped posture with kyphosis; can be moderately 
leaning to one side. 
4 = Marked flexion with extreme abnormality of posture. 
29. Gait 
0 = Normal. 
1 = Walks slowly, may shuffle with short steps, but no festination 
(hastening steps) or propulsion. 
2 = Walks with difficulty, but requires little or no assistance; may 
have some festination, short steps, 
or propulsion. 
3 = Severe disturbance of gait, requiring assistance. 
4 = Cannot walk at all, even with assistance. 
30. Postural Stability (Response to sudden, strong posterior 
displacement produced by pull on shoulders 
while patient erect with eyes open and feet slightly apart. Patient is 
prepared.) 
0 = Normal. 
1 = Retropulsion, but recovers unaided. 
2 = Absence of postural response; would fall if not caught by 
examiner. 
3 = Very unstable, tends to lose balance spontaneously. 
4 = Unable to stand without assistance. 
31. Body Bradykinesia and Hypokinesia (Combining slowness, 
hesitancy, decreased armswing, small 
amplitude, and poverty of movement in general.) 
0 = None. 
 
 
1 = Minimal slowness, giving movement a deliberate character; could      
be normal for some persons. 
Possibly reduced amplitude. 
2 = Mild degree of slowness and poverty of movement which is 
definitely abnormal. 
Alternatively, some reduced amplitude. 
3 = Moderate slowness, poverty or small amplitude of movemen 
 
 
Epworth Sleepiness Scale  
 
 
0 - would never doze 1- slight chance of dozing 2- moderate chance of dozing 3- 
high chance of dozing  
 
Sitting and reading ________________  
 
Watching TV ________________  
 
Sitting, inactive in a public place (egtheater, meeting) ________________ 
 
 As a passenger in a car for an hour without a break ________________ 
 
Lying down to rest in the afternoon When circumstances permit 
________________  
 
Sitting and talking to someone ________________  
 
Sitting quietly after a lunch without alcohol ________________ 
 
 In a car, while stopped for a few minutes in the traffic ________________  
 
If your score is 10 or more, it suggests that you are abnormally sleepy and need 
further evaluation and treatment 
 
 
 
 
 
 
PDSS SCALE 
 
 
 
S.NO.  AGE  SEX  DURATION  STAGING  SEVERITY  PDSS  ESS  TST(min)  LAT  EFF  NIN2  SWS  REM  RBD  SNOR  AHI  SaO2  PLMS  RLS 
a  50  M  2  2  12  148  0  342  5  89  N  N  3  NO  NO  0  98  0  NO 
2  48  M  3  2  15  144  2  315  5  90  N  N  3  YES  NO  0  98  0  NO 
3  51  F  3  2  16  142  4  375  10  84  N  N  2  NO  NO  2  92  0  NO 
4  60  M  7  4  30  90  10  280  28  66  INC  DEC  2  NO  YES  10  88  8  NO 
5  70  M  12  5  40  82  16  215  45  58  INC  DEC  2  NO  NO  0  98  10  YES 
6  70  F  11  5  40  80  16  210  50  55  INC  DEC  2  NO  YES  10  88  10  YES 
7  50  M  3  3  24  120  0  300  10  70  INC  DEC  2  YES  NO  0  94  8  YES 
8  60  M  6  3  27  106  1  318  25  68  INC  DEC  2  YES  NO  0  99  0  NO 
9  48  F  4  3  26  110  2  320  20  70  INC  DEC  2  NO  NO  0  95  0  NO 
10  50  M  4  2.5  22  134  3  300  20  80  INC  DEC  2  NO  NO  0  96  0  NO 
11  56  M  5  2.5  24  130  5  315  18  70  INC  DEC  1  NO  YES  8  86  0  NO 
12  46  M  7  3  28  110  1  280  30  68  INC  DEC  2  NO  NO  0  94  0  NO 
13  52  M  4  2.5  26  120  12  360  25  76  INC  DEC  2  NO  YES  10  87  0  NO 
14  64  F  5  3  20  138  4  315  35  78  INC  DEC  2  NO  NO  0  96  0  NO 
15  64  F  4  2.5  20  138  2  340  20  78  INC  DEC  2  NO  NO  0  95  0  NO 
16  55  M  3  2  14  146  1  445  2  94  N  N  3  NO  NO  4  90  6  NO 
17  51  M  3  2.5  18  142  2  420  8  85  N  N  2  YES  NO  0  96  0  NO 
18  65  M  7.5  4  32  88  13  255  30  65  INC  DEC  2  NO  YES  8  86  9  YES 
19  67  M  10  4  38  84  12  230  40  56  INC  DEC  2  NO  NO  0  96  8  YES 
20  52  M  4  3  28  102  1  315  12  70  INC  DEC  3  NO  YES  12  85  0  NO 
21  53  M  5  3  26  115  3  330  20  70  INC  DEC  2  NO  NO  0  94  0  NO 
22  54  M  5  3  30  100  14  345  45  78  INC  DEC  2  NO  YES  18  80  0  NO 
23  62  M  6  3  26  124  1  285  22  70  INC  DEC  2  NO  NO  0  92  0  NO 
24  50  M  5  3  20  140  3  345  15  74  INC  DEC  2  NO  NO  0  95  0  NO 
25  66  F  6  2.5  26  120  3  300  25  70  INC  DEC  2  NO  NO  2  92  0  NO 
MASTER  CHART
 
 
 
26  54  M  1  1  10  150  0  375  2  86  N  N  3  NO  NO  0  99  2  NO 
27  60  M  7  4  34  89  11  280  30  62  INC  DEC  1  NO  NO  0  97  8  NO 
28  64  M  7  4  31  82  11  240  35  60  INC  DEC  2  NO  YES  6  88  10  YES 
29  54  M  4  3  25  115  2  285  20  70  INC  DEC  2  NO  NO  10  88  0  NO 
30  55  M  5  3  30  100  15  315  25  70  INC  DEC  2  NO  YES  8  86  10  YES 
31  49  M  6  3  28  110  2  300  25  68  INC  DEC  2  YES  NO  0  95  0  NO 
32  60  M  4  2.5  20  140  3  340  20  76  INC  DEC  2  NO  NO  0  96  0  NO 
33  56  M  6  2.5  30  100  4  310  30  70  INC  DEC  2  YES  NO  0  85  0  NO 
34  68  F  7  3  30  98  4  280  20  68  INC  DEC  2  YES  NO  0  98  0  NO 
35  60  F  5  3  26  120  3  335  25  76  INC  DEC  2  NO  NO  2  93  0  NO 
36  60  M  1  1.5  11  145  0  300  6  90  N  N  3  NO  NO  0  97  2  NO 
37  55  M  4  2.5  19  140  4  330  10  86  N  N  3  NO  YES  6  89  6  NO 
38  61  M  8  4  36  86  14  275  25  62  INC  DEC  2  NO  NO  0  99  6  NO 
39  65  F  8  4  33  84  12  260  25  60  INC  DEC  2  NO  NO  3  90  10  YES 
40  58  M  6  3  27  108  3  295  22  66  INC  DEC  1  NO  YES  10  88  0  NO 
41  56  F  5  3  28  105  4  310  20  68  INC  DEC  2  NO  NO  0  96  0  NO 
42  52  M  4  2  22  132  1  330  20  70  INC  DEC  2  NO  NO  0  94  0  NO 
43  65  M  5  3  30  100  14  310  40  78  INC  DEC  2  NO  YES  20  80  0  NO 
44  60  M  4  2.5  22  130  16  300  40  80  INC  DEC  2  YES  NO  10  85  0  NO 
45  62  F  4  2.5  20  136  3  300  22  74  INC  DEC  2  NO  NO  0  95  0  NO 
46  48  F  4  2.5  18  142  3  320  5  90  N  N  3  NO  YES  8  88  4  NO 
47  66  F  10  4  35  88  14  265  30  63  INC  DEC  2  NO  NO  0  97  8  YES 
48  58  F  6  3  29  102  14  300  24  66  INC  DEC  2  YES  YES  16  81  10  YES 
49  48  M  6  2  30  96  2  300  20  70  INC  DEC  2  YES  NO  0  95  0  NO 
50  50  F  3.5  2  16  144  3  405  12  84  N  N  3  NO  NO  0  95  0  NO 
 
   
 
